Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review.
Oh WK, McDermott D, Porta C, Levy A, Elaidi R, Scotte F, Hawkins R, Castellano D, Bellmunt J, Rha SY, Sun JM, Nathan P, Feinberg BA, Scott J, McDermott R, Ahn JH, Wagstaff J, Chang YH, Ou YC, Donnellan P, Huang CY, McCaffrey J, Chiang PH, Chuang CK, Korves C, Neary MP, Diaz JR, Mehmud F, Duh MS. Oh WK, et al. Among authors: mehmud f. Int J Oncol. 2014 Jan;44(1):5-16. doi: 10.3892/ijo.2013.2181. Epub 2013 Nov 15. Int J Oncol. 2014. PMID: 24247547 Free PMC article.
Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study.
Escudier B, Porta C, Bono P, Powles T, Eisen T, Sternberg CN, Gschwend JE, De Giorgi U, Parikh O, Hawkins R, Sevin E, Négrier S, Khan S, Diaz J, Redhu S, Mehmud F, Cella D. Escudier B, et al. Among authors: mehmud f. J Clin Oncol. 2014 May 10;32(14):1412-8. doi: 10.1200/JCO.2013.50.8267. Epub 2014 Mar 31. J Clin Oncol. 2014. PMID: 24687826 Clinical Trial.
Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries.
Porta C, Levy A, Hawkins R, Castellano D, Bellmunt J, Nathan P, McDermott R, Wagstaff J, Donnellan P, McCaffrey J, Vekeman F, Neary MP, Diaz J, Mehmud F, Duh MS. Porta C, et al. Among authors: mehmud f. Cancer Med. 2014 Dec;3(6):1517-26. doi: 10.1002/cam4.302. Epub 2014 Jul 18. Cancer Med. 2014. PMID: 25045157 Free PMC article.
Reply to S. Barni et Al and M. Sun et Al.
Escudier B, Porta C, Powles T, Eisen T, Sternberg CN, Mehmud F, Cella D. Escudier B, et al. Among authors: mehmud f. J Clin Oncol. 2014 Nov 20;32(33):3783-4. doi: 10.1200/JCO.2014.57.9219. Epub 2014 Sep 29. J Clin Oncol. 2014. PMID: 25267750 No abstract available.
Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study.
André T, Reyes-Vidal JM, Fartoux L, Ross P, Leslie M, Rosmorduc O, Clemens MR, Louvet C, Perez N, Mehmud F, Scheithauer W. André T, et al. Among authors: mehmud f. Br J Cancer. 2008 Sep 16;99(6):862-7. doi: 10.1038/sj.bjc.6604628. Br J Cancer. 2008. PMID: 19238628 Free PMC article. Clinical Trial.
The changing face of venous thromboembolism management in England.
Ramagopalan SV, Carroll R, Ulvestad M, Mehmud F, Alikhan R. Ramagopalan SV, et al. Among authors: mehmud f. Future Cardiol. 2019 May;15(3):183-185. doi: 10.2217/fca-2019-0003. Epub 2019 Mar 25. Future Cardiol. 2019. PMID: 30907131 Free article. Review.
19 results